[Skip to Navigation]
August 13, 2020

Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy

Author Affiliations
  • 1Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston
JAMA Ophthalmol. 2020;138(10):1101-1103. doi:10.1001/jamaophthalmol.2020.2778

Erdafitinib received accelerated approval from the US Food and Drug Administration in April 2019 after a phase 2 trial for locally advanced or metastatic urothelial carcinoma.1 It works as a tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) 1 to 4 (pan-FGFR inhibitor) and is the first FGFR kinase inhibitor approved by the US Food and Drug Administration.1 Retinal findings were noted in the phase 2 trial.

Add or change institution